Haisco partners with AbbVie for pain drugs
Haisco Pharmaceutical has granted AbbVie exclusive global rights, excluding mainland China, Hong Kong, and Macau, to develop and commercialize its pain management drug candidates. Haisco will receive a USD 30 million upfront payment and up to USD 715 million in potential milestone payments, plus tiered royalties on future net sales.